MANNKIND CORP (MNKD)
US56400P7069 - Common Stock
Noteworthy Wednesday Option Activity: MNKD, BTU, FSLR
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH...
MannKind Becomes Oversold (MNKD)
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®) ...
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India...
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024.
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ...
MannKind to Present at 2024 UBS Healthcare Conference
MannKind to Present at 2024 UBS Healthcare Conference
MannKind to Present at 2024 UBS Healthcare Conference...
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases ...
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
Mannkind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 ...
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease...
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham...
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN...
マンカインド (MannKind) 、非結核性抗酸菌症（NTM）肺疾患治療用クロファジミン (Clofazimine) 吸入懸濁液の日本における第 3 相臨床試験（ICoN-1）開始に向けたPMDA承認取得を発表
韓国とオーストラリアの保健当局からも承認取得、台湾は2024年第4四半期に承認取得予定米国で初の患者無作為化 コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) --...
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment...
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development...
MannKind to Present at Upcoming Conferences
MannKind to Present at Upcoming Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development...
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD...
MannKind (MNKD) Q2 2024 Earnings Call Transcript
MNKD earnings call for the period ending June 30, 2024.
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 9:00 a.m. (ET)
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 9:00 a.m. (ET)...
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease...
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
MANNKIND CORPORATION TO HOLD 2024 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 7, 2024...